Biostime launches Probi’s probiotic in China

Dietary supplements with Probi’s healthy bacteria Lp299v will be launched in China during the spring of 2007. Probi’s partner, Institut Rosell-Lallemand, has signed an exclusive agreement for launch of their dietary supplements on the Chinese market with the leading domestic health food company Biostime Inc.

Dietary supplements with Probi’s healthy bacteria Lp299v will be launched in China during the spring of 2007. Probi’s partner, Institut Rosell-Lallemand, has signed an exclusive agreement for launch of their dietary supplements on the Chinese market with the leading domestic health food company Biostime Inc.

Biostime Inc. was the first health food company to launch a probiotic six years ago for enhancement of the body’s natural defences in children. Today Biostime continues to be the leader in the probiotic supplement market in China with a nationwide coverage and an annual growth of 15 percent.

“We are proud that Biostime opted for our probiotics. We estimate that high quality products marketed by the best distributors will help to develop Probi´s share of the market substantially,” says Per-Ola Forsberg, Executive Vice President of Probi.

“As a probiotic supplement leader in China, it is natural to expand our product portfolio to a highly documented probiotic like Lp299v, targeting a specific health condition as Irritable Bowel Syndrome. We expect that, just like the great success we had with Biostime Probiotic Sachet for Children, the Lp299v based supplement will become a very successful product, and more importantly, it will benefit millions of IBS sufferers,” says Fei Luo, CEO of Biostime Inc.

Probi and Institut Rosell-Lallemand collaborate on the commercialization of Probi’s Lp299v bacterium within Dietary Supplements. Institut Rosell-Lallemand is a major vendor of probiotic dietary supplements in the US and Europe, and is considered to be the player that will confer Probi with the fastest market penetration.

This new agreement means that sales of dietary supplements with Probi’s probiotics are underway in the UK, France, Germany, Scandinavia, the US, Canada, South Africa, Australia and China. The estimated total value of the global market for probiotic dietary supplements is some SEK 7 billion, and has traced an annual growth rate of over 10 percent in recent years.


For further information please contact:

Per-Ola Forsberg, Executive Vice President, tel: +46 (0)46 286 8926 or +46 (0)73 344 8384 e-mail: per-ola.forsberg@probi.se
Rolf Bjerndell, Acting CEO, tel: +46 (0)46 286 8923 or +46 (0)70 515 3009 e-mail: rolf.bjerndell@probi.se
Olivier Clech, President Institut Rosell/Lallemand, phone: + 33 (0)611 30 26 31 e-mail: oclech@lallemand.com

About Us

Probi AB is a Swedish publicly traded biotechnology company that develops effective and well-documented probiotics. Through its research, Probi has created a strong product portfolio in the gastrointestinal health and immune system areas. The products are available to consumers in more than 40 countries worldwide. The customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. The Probi share is listed on NASDAQ OMX Stockholm, Mid-cap. Read more on www.probi.se.

Contacts

Subscribe

Documents & Links